PE20090714A1 - Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido - Google Patents
Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipidoInfo
- Publication number
- PE20090714A1 PE20090714A1 PE2008000821A PE2008000821A PE20090714A1 PE 20090714 A1 PE20090714 A1 PE 20090714A1 PE 2008000821 A PE2008000821 A PE 2008000821A PE 2008000821 A PE2008000821 A PE 2008000821A PE 20090714 A1 PE20090714 A1 PE 20090714A1
- Authority
- PE
- Peru
- Prior art keywords
- imidazopyridazines
- pyrolo
- kinase inhibitors
- dimetoxy
- imidazo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
REFERIDA A COMPUESTOS DE FORMULA (I): DONDE X E Y SON CADA UNO N, C; R1 Y R2 SON CADA UNO ARILO SUSTITUIDO O NO, HETEROCICLILO SUSTITUIDO O NO, N-OXIDO, ENTRE OTROS. SON COMPUESTOS SELECCIONADOS: 3,6-BIS-(3,4-DIMETOXI-FENIL)-IMIDAZO-[1,2-b]-PIRIDAZINA; 4-[6-(3,4-DIMETOXI-FENIL)-IMIDAZO-[1,2-b]-PIRIDAZIN-3-IL]-BENZAMIDA; 5-[6-(3,4-DIMETOXI-FENIL)-IMIDAZO-[1,2-b]-PIRIDAZIN-3-IL]-3-TRIFLUORO-METIL-PIRIDIN-2-IL-AMINA; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CINASA -PI3, UTILES EN EL TRATAMIENTO CONJUNTIVITIS, ANEMIA HEMOLITICA, ENGERMEDAD DE CROHN, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91734807P | 2007-05-11 | 2007-05-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20090714A1 true PE20090714A1 (es) | 2009-07-17 |
Family
ID=39769090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2008000821A PE20090714A1 (es) | 2007-05-11 | 2008-05-09 | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido |
Country Status (17)
Country | Link |
---|---|
US (1) | US20100311729A1 (es) |
EP (1) | EP2155202A2 (es) |
JP (1) | JP2010526795A (es) |
KR (1) | KR20100016460A (es) |
CN (1) | CN101678026A (es) |
AR (1) | AR067326A1 (es) |
AU (1) | AU2008250293A1 (es) |
BR (1) | BRPI0811600A2 (es) |
CA (1) | CA2686903A1 (es) |
CL (1) | CL2008001364A1 (es) |
EA (1) | EA200901505A1 (es) |
MX (1) | MX2009012127A (es) |
PA (1) | PA8780101A1 (es) |
PE (1) | PE20090714A1 (es) |
TW (1) | TW200911810A (es) |
UY (1) | UY31076A1 (es) |
WO (1) | WO2008138889A2 (es) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
EP2231661A1 (en) | 2007-12-19 | 2010-09-29 | Amgen, Inc. | Inhibitors of pi3 kinase |
WO2009140128A2 (en) | 2008-05-13 | 2009-11-19 | Irm Llc | Compounds and compositions as kinase inhibitors |
FR2939134A1 (fr) * | 2008-12-01 | 2010-06-04 | Sanofi Aventis | Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique |
WO2010108074A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
MX2011012037A (es) * | 2009-05-13 | 2012-02-28 | Amgen Inc | Compuestos de heteroarilo como inhibidores de pikk. |
EP2563792B1 (en) * | 2010-04-28 | 2014-08-27 | Bristol-Myers Squibb Company | Imidazopyridazinyl compounds and their uses for cancer |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
WO2013028263A1 (en) * | 2011-08-24 | 2013-02-28 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as pi3 kinase inhibitors |
UA111382C2 (uk) | 2011-10-10 | 2016-04-25 | Оріон Корпорейшн | Інгібітори протеїнкінази |
GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
KR20160027219A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
US9988386B2 (en) | 2013-05-30 | 2018-06-05 | Kata Pharmaceuticals, Inc. | Compounds for treatment of diseases of abnormal angiogenesis or aberrant growth factors and uses thereof |
AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并[1,5-a]嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
CN103864800A (zh) * | 2014-04-03 | 2014-06-18 | 定陶县友帮化工有限公司 | 6-氯咪唑并[1,2-b]哒嗪的合成方法 |
EP3215509B1 (en) | 2014-11-06 | 2020-02-26 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
CN107001379B (zh) | 2014-11-06 | 2022-11-01 | Bial研发投资股份有限公司 | 取代的吡唑并[1,5-a]嘧啶以及它们在治疗医学障碍中的用途 |
US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US10253045B2 (en) | 2014-11-26 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
CN107820425B (zh) | 2015-06-15 | 2021-08-31 | Nmd制药股份公司 | 用于治疗神经肌肉病症的化合物 |
PE20180572A1 (es) | 2015-06-18 | 2018-04-04 | Cephalon Inc | Derivados de piperidina 1,4-sustituidos |
ES2849951T3 (es) | 2015-06-18 | 2021-08-24 | 89Bio Ltd | Derivados de piperidina 4-bencil y 4-benzoil sustituidos |
JP2018531957A (ja) | 2015-10-27 | 2018-11-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害薬としての置換二環式ピラゾール化合物及びその使用 |
MX2018005004A (es) | 2015-10-27 | 2018-09-12 | Merck Sharp & Dohme | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. |
EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
BR112018070586A8 (pt) | 2016-04-06 | 2023-04-11 | Lysosomal Therapeutics Inc | Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos |
CA3020310A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
EP3452481A4 (en) | 2016-05-05 | 2020-02-26 | Lysosomal Therapeutics Inc. | IMIDAZO [1,2-B] SUBSTITUTED PYRIDAZINES, IMIDAZO [1,5-B] SUBSTITUTED PYRIDAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
KR101798840B1 (ko) * | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11667651B2 (en) | 2017-12-22 | 2023-06-06 | Hibercell, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
CN108186644A (zh) * | 2018-01-24 | 2018-06-22 | 重庆莱契科技有限公司 | 化合物的用途 |
US20210221817A1 (en) * | 2018-08-31 | 2021-07-22 | Nivien Therapeutics Compny | Novel heteroaromatic compounds as potent modulators of the hippo-yap signaling pathway lats1/2 kinases |
CN114206332A (zh) * | 2019-06-04 | 2022-03-18 | 艾库斯生物科学有限公司 | 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物 |
CN111333655B (zh) * | 2020-04-13 | 2021-07-13 | 武汉工程大学 | 一种***并嘧啶类化合物及其制备方法和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662826B2 (en) * | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
WO2004052315A2 (en) * | 2002-12-11 | 2004-06-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2007013673A1 (en) * | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
CN101273040B (zh) * | 2005-09-27 | 2011-11-09 | 弗·哈夫曼-拉罗切有限公司 | 作为mglur2拮抗剂的*二唑基吡唑并嘧啶类化合物 |
US8268809B2 (en) * | 2006-09-05 | 2012-09-18 | Emory University | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof |
CN101594909A (zh) * | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
WO2008037477A1 (en) * | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as p13k lipid kinase inhibitors |
JP2010508315A (ja) * | 2006-10-30 | 2010-03-18 | ノバルティス アーゲー | 抗炎症剤としてのヘテロ環式化合物 |
CA2667960A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Imidazopyridazines as pi3k lipid kinase inhibitors |
NZ576234A (en) * | 2006-11-06 | 2011-06-30 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
AR064420A1 (es) * | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
US20100305113A1 (en) * | 2007-05-09 | 2010-12-02 | Hans-Georg Capraro | Substituted Imidazopyridazines as Lipid Kinase Inhibitors |
-
2008
- 2008-05-08 AR ARP080101956A patent/AR067326A1/es not_active Application Discontinuation
- 2008-05-09 TW TW097117328A patent/TW200911810A/zh unknown
- 2008-05-09 KR KR1020097023565A patent/KR20100016460A/ko not_active Application Discontinuation
- 2008-05-09 BR BRPI0811600A patent/BRPI0811600A2/pt not_active Application Discontinuation
- 2008-05-09 CA CA002686903A patent/CA2686903A1/en not_active Abandoned
- 2008-05-09 MX MX2009012127A patent/MX2009012127A/es not_active Application Discontinuation
- 2008-05-09 JP JP2010506947A patent/JP2010526795A/ja active Pending
- 2008-05-09 AU AU2008250293A patent/AU2008250293A1/en not_active Abandoned
- 2008-05-09 CN CN200880015653A patent/CN101678026A/zh active Pending
- 2008-05-09 CL CL2008001364A patent/CL2008001364A1/es unknown
- 2008-05-09 EA EA200901505A patent/EA200901505A1/ru unknown
- 2008-05-09 PA PA20088780101A patent/PA8780101A1/es unknown
- 2008-05-09 PE PE2008000821A patent/PE20090714A1/es not_active Application Discontinuation
- 2008-05-09 UY UY31076A patent/UY31076A1/es not_active Application Discontinuation
- 2008-05-09 WO PCT/EP2008/055751 patent/WO2008138889A2/en active Application Filing
- 2008-05-09 EP EP08759487A patent/EP2155202A2/en not_active Withdrawn
- 2008-05-09 US US12/599,143 patent/US20100311729A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA200901505A1 (ru) | 2010-06-30 |
CL2008001364A1 (es) | 2008-12-19 |
AR067326A1 (es) | 2009-10-07 |
US20100311729A1 (en) | 2010-12-09 |
TW200911810A (en) | 2009-03-16 |
JP2010526795A (ja) | 2010-08-05 |
BRPI0811600A2 (pt) | 2019-09-10 |
WO2008138889A8 (en) | 2009-07-09 |
EP2155202A2 (en) | 2010-02-24 |
CA2686903A1 (en) | 2008-11-20 |
PA8780101A1 (es) | 2008-12-18 |
WO2008138889A2 (en) | 2008-11-20 |
MX2009012127A (es) | 2009-11-19 |
KR20100016460A (ko) | 2010-02-12 |
UY31076A1 (es) | 2009-01-05 |
AU2008250293A1 (en) | 2008-11-20 |
CN101678026A (zh) | 2010-03-24 |
WO2008138889A3 (en) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090714A1 (es) | Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido | |
PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
PE20080893A1 (es) | Triazoles biciclicos como moduladores de la proteina cinasa | |
PE20150153A1 (es) | 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 | |
PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
PE20141828A1 (es) | 6-alquinilo piridinas como mimeticos smac | |
PE20090511A1 (es) | Imidazopiridinonas | |
PE20080695A1 (es) | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel | |
CL2012001221A1 (es) | Compuestos derivados de 4 -(1h-pirrol-1-il) pirimidin -2-ilamino y 4 -(1h-pirazol-1-il)- pirimidin-2-ilamino, inhibidores de quinasa; un compuesto isomerico; composicion farmaceutica; utiles en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, colitis ulcerante, enfermedad de crohn, bronquitis, dermatitis, entre otras. | |
PE20130457A1 (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
CL2012000591A1 (es) | Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados. | |
PE20090674A1 (es) | Compuestos multiciclicos | |
ATE457311T1 (de) | Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine | |
PE20091211A1 (es) | Derivados de pirazolopirimidina como moduladores de pde9a | |
ATE531372T1 (de) | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren | |
PE20140397A1 (es) | Derivados de fluoro-piridinona utiles como agentes antibacterianos | |
PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
PE20090492A1 (es) | Compuestos heterociclos como inhibidores de cinasa de fosfatidil-inositol-3 | |
MX2009010728A (es) | Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. | |
PE20091414A1 (es) | FURO [3,2-c] PIRIDINA Y TIENO [3,2-c] PIRIDINAS | |
MY148375A (en) | Delta and epsilon crystal forms of imatinib mesylate | |
PE20110404A1 (es) | Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de la orexina | |
PE20090902A1 (es) | Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |